Drug intelligence / Profile preview

zimlovisertib

Development stage: Phase 2
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Zimlovisertib (PF-06650833) is a potent, selective, and orally active small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). Developed by Pfizer, it was designed to modulate inflammatory signaling pathways downstream of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs). The drug was primarily investigated for the treatment of autoimmune and inflammatory conditions, specifically rheumatoid arthritis (in patients with an inadequate response to methotrexate) and hidradenitis suppurativa. Despite reaching Phase 2 clinical trials for these indications, Pfizer discontinued its development.

Brand names: zimlovisertib
Other names: zimlovisertibPF-6650833PF6650833PF 6650833

Targets

IRAK4 (Interleukin-1 receptor associated kinase 4)

Beyond the preview

Go deeper on zimlovisertib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zimlovisertib.

Explore the full profile